Johnson & Johnson’s Target, Estimates Cut at Goldman Sachs (JNJ)

Share |

Healthcare giant Johnson & Johnson ( JNJ ) on Tuesday saw its price target and earnings estimates lowered by analysts at Goldman Sachs.

The firm said it cut its estimates for JNJ through 2012, citing expectations of a slower recovery. Goldman maintained its "Neutral" rating on JNJ and introduced a new $59 price target, which implies a 6% downside to the stock's Monday closing price of $62.82.

Johnson & Johnson shares rose 36 cents, or +0.6%, in premarket trading Tuesday.

The Bottom Line
We have been recommending shares of Johnson & Johnson ( JNJ ) since Oct.8, 2009, when the stock was trading at $60.71. The company has a 3.44% dividend yield, based on last night's closing stock price of $62.82.

Johnson & Johnson ( JNJ ) is a "Recommended" dividend stock, holding a DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by

This article appears in: Investing , Stocks

Referenced Stocks: JNJ

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by